Director at Nutex Health (NUTX) buys 150 shares in open market

Rhea-AI Filing Summary

Nutex Health Inc. director Frank E. Jaumot bought 150 shares of common stock in an open-market purchase. The transaction took place on March 20, 2026 at a price of $93.555 per share. After this trade, he directly holds 150 Nutex Health shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaumot Frank E

(Last) (First) (Middle)

1776 YORKTOWN STREET

C/O NUTEX HEALTH INC.

(Street)

HOUSTON TEXAS 77056

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		P		150	A	$93.555	150	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Frank E. Jaumot	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nutex Health (NUTX) director Frank E. Jaumot report?

Director Frank E. Jaumot reported an open-market purchase of 150 shares of Nutex Health common stock. The transaction occurred on March 20, 2026, and was reported on Form 4 as a non-derivative transaction, showing direct ownership of the purchased shares.

At what price did the Nutex Health (NUTX) director buy his shares?

Frank E. Jaumot bought his 150 Nutex Health common shares at a price of $93.555 per share. This price is the transaction’s reported average per-share amount for the open-market purchase recorded on March 20, 2026, in the Form 4 filing.

How many Nutex Health (NUTX) shares does the director hold after the reported trade?

Following the transaction, Frank E. Jaumot directly owns 150 Nutex Health common shares. The Form 4 filing lists this figure as the total shares beneficially owned after the March 20, 2026 open-market purchase, with no derivative positions reported in this filing.

Was the Nutex Health (NUTX) insider transaction a buy or a sell?

The reported Nutex Health insider transaction was a buy. Director Frank E. Jaumot executed an open-market purchase of 150 common shares, coded as “P” for purchase, with the filing’s transaction summary showing a net-buy direction of 150 shares.

Does the Nutex Health (NUTX) Form 4 show any derivative transactions for the director?

No derivative transactions are shown for Frank E. Jaumot in this Form 4. The filing reports only a single non-derivative open-market purchase of 150 Nutex Health common shares, and the derivative transaction count and shares are both listed as zero.